Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Overview
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor
Clarity PharmaceuticalsPhase
Phase 1/2
Contacts
Clarity Pharmaceuticals (Clarity Clinical)
clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
ClinicalTrials.gov
NCT04868604Eligibility
Patient Education
Patient education not yet provided.
Publications
Publications not yet provided.
Locations
Loading…
Help us improve your experience